Company Long-Term Loans and Borrowings: Elevai Skincare (ELAB)

Public company logo of Elevai Skincare (ELAB)

Elevai Labs Inc. (ELAB) creates innovative exosome-based cosmetic products targeting dermatologists and aesthetic centers. The stock price history reflects debt obligation dynamics, which currently stand at 0.01. The business relies on contract manufacturing and third-party logistics, utilizing cloud IT solutions. Meanwhile, the company maintains high resilience to global conflicts due to the neutral status of the biomedical industry.

ELAB Elevai Labs Inc. Company Long-Term Debts (02/21/2024 - 10/30/2026)

Summary analytical data breakdowns for Elevai Skincare (ELAB)

- market price and analyst price targets:
Stock Price elevaiskincare.com|ELAB - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Elevai Labs|ELAB - Total Company Value
- book capitalization information:
Accounting Value per Share Elevai Labs|ELAB - Book Capitalization|Market Capitalization to Book Value Ratio elevaiskincare.com|ELAB - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Elevai Labs Inc.|ELAB - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Elevai Corp|ELAB - Company Debts|Debts to Book Capitalization Elevai Labs|ELAB - Company Long-Term Debts|Short-Term Debt Volume Elevai Labs|Immediate Liquidity Ratio elevaiskincare.com
- earnings and multiples data:
ELAB - Net Profit
Analysis of all company metrics:ELAB (elevaiskincare.com)
Brand item of Elevai Labs Inc.

Complex cold-chain bio-logistics for exosome delivery require significant capital expenditures in infrastructure. The scaling of such costs is often reflected in the long-term liability trends of Elevai Labs Inc. (ELAB). This indicator captures the total debt with a maturity period exceeding twelve months. An increase in this metric may signal either strategic development or a liquidity deficit. By analyzing the company's long-term debt levels, an investor determines the financial stability of the asset.

Who Elevai Labs Inc. competes with

Company Long-Term Debts krystalbio.com KRYS|APGE - Company Long-Term Debt|Company Long-Term Loans and Borrowings ARQT (Arcutis)|Vericel Corp. (VCEL) - Company Long-Term Debt|Company Long-Term Liabilities Oruka Pharma|SMTI (Sanara MedTech, Inc.) - Company Long-Term Debts|Company Long-Term Debts DBV Technologies SA|Company Long-Term Liabilities SLSN (Solesence Inc)|DERM (journeymedicalcorp.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Forte Biosciences, Inc FBRX|Long-Term Debt Volume Empro Corporation (EMPG)|SLGL - Company Long-Term Debt|AXIL - Company Long-Term Debts|MDCX: Company Long-Term Debts|VRCA - Long-Term Debt Volume|Company Long-Term Debt Hoth Therapeutics Inc.|Company Long-Term Indebtedness BFRI (Biofrontera Inc)|Company Long-Term Debts VYNE|SNOA - Long-Term Debt|Company Long-Term Debt Quoin Pharmaceuticals Ltd. QNRX|Azitra Inc - Company Long-Term Debt|Dermata - Company Long-Term Debts|Long-Term Debt Revance Therapeutics Inc